glp-1 vs gip & Agonists | Obesity and Diabetes Management | Harrison's updates (22nd Ed.) GI Adverse Effects of Glucagon-Like
Description
Obesity has further been associated with higher disease activity and reduced time to flare
Discover insights on discontinuation rates
Records were reviewed for patient characteristics and medication type and doses
Learn the science
This review highlights key clinical considerations across reproductive stages, emphasizes the primacy of human exposure data where available, and identifies critical evidence gaps requiring future prospective study.
Only one of those is GLP-1
